Skip to main content
OpenTrials
Completed

NCT Number: NCT02483130

Effect of N-acetylcysteine on Brain Glutamate

A double-blind, placebo controlled, crossover study to determine whether a single dose of N-acetylcysteine (a nutritional supplement) can reduce brain glutamate levels in patients with a psychotic disorder. Secondary outcomes are to determine the pattern of alteration in brain perfusion and activity following a single dose of N-acetylcysteine.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institute of Psychiatry, Psychology and Neuroscience

Denmark Hill, London, SE5 8AF, United Kingdom

About this study

This is a physiological, proof-of-concept study designed to investigate whether a single administration of N-acetylcysteine can reduce brain glutamate levels in people with psychotic disorders.

Previous research suggests that poor response to antipsychotics may be linked to increased levels of glutamate in the brain (Egerton et al., 2012; Demjaha, Egerton et al., 2013). Reducing brain glutamate levels may therefore be therapeutic. This study tests whether it is possible to reduce brain glutamate levels in psychotic disorders.

This is a small pilot study to determine whether a single administration of NAC can reduce brain glutamate levels in psychosis. At the same time, we will also examine the effects of NAC on brain resting perfusion and activity, to gain more information about how NAC may be acting.

This study will recruit participants with a previous diagnosis of a psychotic disorder. There will be three study visits, 1-2 weeks apart. The first visit will involve a physical health check, blood sample and an interview to assess current symptoms and confirm medical history. On the second and third visits participants will have an MRI scan, lasting one hour, after taking capsules containing either 2400mg NAC or placebo.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Over 18 years of age
  • Diagnosis of a psychotic disorder
  • Have mental capacity to consent

Exclusion criteria

  • Diagnosed drug or alcohol dependency, with the exception of nicotine
  • Pregnancy, as determined through a urine pregnancy test
  • Presence of any physical health abnormality which may impact on safety to participate in the research, as determined by a study clinician on the basis of the physical health check and the available medical information.
  • Presence of electronic or metallic implants contraindicated to MRI scanning at 3 Tesla, or presence of any other contraindication to MRI
  • History of asthma
  • History of epilepsy or any other seizure
  • Under 18 years of age
  • Lacking mental capacity to consent
  • Current or previous use of NAC
  • Currently prescribed clozapine

Treatment and study plan

N-acetylcysteine

Dietary Supplement

Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.

Placebo

Other

Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.

Primary outcomes

  1. Reduction in brain glutamate

    Time frame: One hour post capsule

    The within-subjects difference in brain glutamate concentration following a single oral administration of placebo compared to 2400mg N-acetylcysteine

Secondary outcomes

  1. Brain perfusion

    Time frame: One hour post capsule

    The within-subjects change in regional brain perfusion, as assessed using pulsed continuous arterial spin labelling (pCASL) MRI, following a single oral administration of placebo compared to 2400mg N-acetylcysteine.

  2. Regional activity and connectivity

    Time frame: One hour post capsule

    The within-subjects change in regional brain activity or connectivity, as assessed using resting state functional magnetic resonance imaging (rsfMRI), following a single oral administration of placebo compared to 2400mg N-acetylcysteine.

Sponsors and collaborators

Lead sponsor

King's College London

Other

Registry information

Official study title

A Randomised Controlled Double Blind Crossover Study of the Effect of a Single Dose of N-acetylcysteine Versus Placebo on Brain Glutamate in Patients With Psychotic Disorders

Acronym: NAC

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Jun 26, 2015
Registry last updated
Mar 8, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.